WHO Expert Committee on Drug Dependence. Critical Review Cannabis and cannabis resin © World Health Organization 2018 Cannabis and cannabis resin Section 1: Chemistry 1. Substance identification ............................................................................................... 4 1.1 International Nonproprietary Name (INN) .............................................................................................. 4 1.2 Chemical Abstract Service (CAS) registry number ................................................................................... 4 1.3 Other chemical names ............................................................................................................................ 4 1.4 Trade names ........................................................................................................................................... 4 Cannabis 1.4.1 plant .................................................................................................................................. 4 1.4.2 Cannabis resin .................................................................................................................................. 5 1.5 Street names ........................................................................................................................................... 5 1.5.1 Cannabis plant .................................................................................................................................. 5 1.5.2 Cannabis resin .................................................................................................................................. 5 1.6 Physical appearance ............................................................................................................................... 6 1.6.1 Cannabis plant .................................................................................................................................. 6 1.6.2 Cannabis resin .................................................................................................................................. 6 1.7 WHO review history ................................................................................................................................ 7 2. Chemistry ..................................................................................................................... 8 2.1 Name ...................................................................................................................................................... 8 2.2 Chemical name ....................................................................................................................................... 8 2.2.1 IUPAC name: ..................................................................................................................................... 8 2.2.2 CA index [...]
Lire la suiteAnalysis of adulterants in prepared bhang from different Authorized bhang shops Shrawan Kumar Sadawarti, Lav Kesharwani, A. K. Jain, Vaibhav Saran, A. K. Gupta Academic Journal of Forensic Sciences, Volume 01 | Issue 02 | October-2018 Available online at : www.xournals.com Abstract : Cannabis is a tall, erect, annual, dioecious herb, provided with an open sunny environment, light, well-drained composted soil and ample irrigation. Bhang is obtained from cut tops of uncultivated plants and is least potent. The potency depends upon the concentration of Tetrahydrocannabinol (THC). It is a narcotic drug and is analgesic in nature. Bhang is prepared by crushing the leaf of cannabis [...]
Lire la suiteCannabis récréatif et politique: oui ou non, Emmanuel Macron est-il contre sa légalisation ? 19 juin 2019 jean-yves nau addictions, alcoolisme, Argent, législatif, Médecine, Polémique, Politique, Pouvoir, Risques (réduction des), tabagisme, Toxicomanies Étiquettes : L'Obs https://jeanyvesnau.com/2019/06/19/cannabis-recreatif-et-politique-oui-ou-non-emmanuel-macron-est-il-contre-sa-legalisation/ Bonjour Pour un peu le journaliste se lasserait. Des députés de quatre groupes politiques (dont certains macronistes) prônent désormais ouvertement une « légalisation contrôlée » du cannabis – et ce dans une proposition de loi transmise de mardi 18 juin à la presse. Ce texte sera officiellement déposé ce 19 juin. Signataires : François-Michel Lambert, Sylvia Pinel, Paul Molac, Jean-Michel Clément, Jeanine Dubié, Frédérique Dumas, François Pupponi (Libertés et territoires), Delphine Bagarry, Annie Chapelier, Hubert Julien-Laferrière, Pierre-Alain Raphan [...]
Lire la suiteL’appel de 70 médecins, élus, économistes : « Pourquoi nous voulons légaliser le cannabis » La une de « l’Obs », du 20 au 26 juin 2019. (« L’Obs ») EXCLUSIF. Dénonçant la faillite de la politique de répression, 70 personnalités – Glucksmann, Jadot, Kouchner… – appellent à la légalisation du cannabis. Par L'Obs Publié le 19 juin 2019 à 06h30 En matière de cannabis, le tout-répressif ne marche pas. Alors sortons de cette politique coûteuse et inefficace. « L’Obs » lance avec plus de 70 économistes, médecins, politiques un appel à une légalisation encadrée. Objectifs prioritaires : la protection des mineurs, la sécurité [...]
Lire la suiteCannabis Use in Pregnancy. A Tale of 2 Concerns Michael Silverstein, MD, MPH1,2; Elizabeth A. Howell, MD, MPH3; Barry Zuckerman, MD1 JAMA. Published online June 18, 2019. doi:10.1001/jama.2019.8860 Original Investigation Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes Daniel J. Corsi, PhD; Laura Walsh, MSc; Deborah Weiss, PhD; Helen Hsu, MD; Darine El-Chaar, MD; Steven Hawken, PhD; Deshayne B. Fell, PhD; Mark Walker, MD Research Letter Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States Nora D. Volkow, MD; Beth Han, MD, PhD, MPH; Wilson M. Compton, MD, MPE; Elinore F. McCance-Katz, MD, PhD Full Text, https://jamanetwork.com/journals/jama/article-abstract/2736581 In an article in JAMA, Corsi and colleagues1 present the results of a retrospective cohort study of 661 617 women designed to assess associations between maternal cannabis use during pregnancy and adverse obstetrical and [...]
Lire la suiteAssociation Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes Daniel J. Corsi, PhD; LauraWalsh, MSc; DeborahWeiss, PhD; Helen Hsu, MD; Darine El-Chaar, MD; Steven Hawken, PhD; Deshayne B. Fell, PhD; MarkWalker,MD JAMA, Published online June 18, 2019. doi:10.1001/jama.2019.8734 Key Points Question Is there an association between prenatal cannabis exposure and maternal, perinatal, and neonatal outcomes? Findings In this retrospective cohort study that included 661 617 pregnancies and 9427 reported cannabis users, the rate of preterm birth among reported cannabis users was 12% vs 6% in nonusers, a statistically significant difference. Meaning Reported cannabis use in pregnancy was associated with significant increases in the rate of preterm [...]
Lire la suiteModern History of Medical Cannabis : From Widespread Use to Prohibitionism and Back Simona Pisanti and Maurizio Bifulco Trends in Pharmacological Sciences, Cell Press, 2017, 38, 3, 195-198. doi: 10.1016/j.tips.2016.12.002. Over the history of pharmacology there are numerous examples of drugs being widely distributed, almost ‘trendy’, prescribed by physicians in a certain period as a sort of panacea, and then neglected, forgotten, or even forbidden as they become considered dangerous in the light of clinical observations. One of these drugs is Cannabis, which was very popular in the 19th century until disappearing from the official Pharmacopoeia at the beginning of the 20th century and [...]
Lire la suiteIntroduction to Recent Advances in Cannabinoid Research Robert B. Laprairie and Will Costain © 2016 The Author(s). Licensee InTechOpen. This chapter is distributed under the terms of the Creative Commons; Attribution License (http://creativecommons.org/licenses/by/3.0), Abstract On October 17, 2018, Canada became the first G20 nation to legalize the use of Cannabis sativa for both medicinal and recreational purposes. This change in legislation and end of prohibition are indicative of a larger global movement to understand Cannabis—and the bioactive chemicals present within Cannabis known as the cannabinoids—for its potential biomedical uses, harms, and economic values. Currently, interest in Cannabis and cannabinoid research is surging as the many [...]
Lire la suiteThe Need for Federal Regulation of Marijuana Marketing John W. Ayers, PhD, Theodore Caputi, Eric C. Leas, PhD,MPH JAMA, June 11, 2019 Volume 321, Number 22 doi:10.1001/jama.2019.4432 A national for-profit marijuana industry is expanding substantially in the United States. Thirty-three states have legalized medical marijuana, 10 of which (where 1 in 4 individuals reside) have also legalized recreational marijuana. Sales of marijuana are projected to increase from $8.5 billion to $75 billion by 2030, rivaling current tobacco sales ($125 billion).1 The initial marijuana marketplace was limited to a few states, but emerging brands have developed sophisticated national marketing campaigns that could potentially have an [...]
Lire la suiteCSSS-N Commissions de la sécurité sociale et de la santé publique Secrétariat CH-3003 Berne www.parlament.ch sgk.csss@parl.admin.ch Vendredi, 03 mai 2019 15h50 Communiqué de presse Essais pilotes avec du cannabis: premier obstacle franchi La Commission de la sécurité sociale et de la santé publique du Conseil national est entrée en matière sur le projet prévoyant la création d’un article relatif aux projets pilotes dans la loi sur les stupéfiants. Elle souhaite permettre la réalisation d’études scientifiques sur la remise contrôlée de cannabis en vue d’une consommation récréative. Par 12 voix contre 9 et 2 abstentions, la Commission de la sécurité sociale et de la santé publique [...]
Lire la suite